Proactiveinvestors United Kingdom OptiBiotix Health PLC Proactiveinvestors United Kingdom OptiBiotix Health PLC RSS feed en Tue, 25 Jun 2019 16:28:54 +0100 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[RNS press release - Appointment of goetzpartners securities Limited ]]> Tue, 25 Jun 2019 07:00:14 +0100 <![CDATA[News - OptiBiotix inks North America deal for weight management product ]]> OptiBiotix Health PLC (LON:OPTI) has inked an exclusive manufacturing and distribution deal that will see the company’s weight loss product rolled out across the US, Canada and Mexico.

It has teamed up with Agropur, a Quebec-based dairy co-operative that notched sales of US$6.7bn last year, to bring SlimBiome to the world’s largest marketplace.

The US weight management market alone is worth an estimated US$72bn.

“We chose Agropur due to their world leading expertise in manufacturing and distributing specialty ingredients like SlimBiome and their reputation for supplying high quality products to the food industry,” said Fred Narbel, managing director of OptiBiotix's prebiotics division.

“We believe working with Agropur, and similar partners around the world, provides the best opportunity of increasing our global commercial reach and catering to the growing interest we are seeing in SlimBiome from partners worldwide."

As well as weight management, the group is developing products to tackle high cholesterol, diabetes and skin problems.

They have been created to interact with the human micro-biome, an ecosystem of bacteria that exists in the gut and on the skin.

Mon, 24 Jun 2019 07:19:00 +0100
<![CDATA[RNS press release - Manufacturing agreement with Agropur ]]> Mon, 24 Jun 2019 07:00:06 +0100 <![CDATA[RNS press release - Result of AGM ]]> Tue, 11 Jun 2019 16:55:01 +0100 <![CDATA[News - OptiBiotix Health signs license deal to sell cholesterol management supplements in Vietnam ]]> OptiBiotix Health PLC (LON:OPTI) has struck a deal with a local distributor to market its ProBiotix arm’s cholesterol management products in Vietnam.

ProBiotix has signed a three-year licence deal with Singapore-based Biovagen Healthcare for its Vietnam subsidiary Viet Phap to exclusively market the CholBiome and CholBiome x3 products in the south-east Asian country.

READ: OptiBiotix Health - the commercial momentum continues to build

Biovagen, which will cover the costs of registering the products with local health authorities, is only guaranteed market exclusivity if it hits minimum sales orders.

OptiBiotix said Biovagen will need to secure half the minimum quantity for the first year within six months of signing the agreement to maximise the financial return for both sides.

The AIM-listed group, which has been mulling a potential spin-off float of the ProBiotix business, said Vietnam was a key market, with a fast growing population and economy, including a rapidly-ageing population where cardiovascular disease is responsible for 31% of all deaths and around 20% of the population suffers from high blood pressure.

OptiBiotix said the Biovagen agreement was “a strategic step” to take the CholBiome products to international markets under its own OptiBiotix brand label or white label distributors brand products.

WATCH: OptiBiotix appoints US-based chief executive for ProBiotix Health

“As manufacturing volumes increase the unit costs of each product decreases improving OptiBiotix's margins. This strategy also creates a global demand for OptiBiotix's cholesterol LPLDL probiotic within CholBiome products which helps build brand recognition and brand value.”

Viet Phap, which currently represents some of the main global generic drugs, specialty pharmaceuticals and probiotics companies, will market CholBiome, which includes probiotic strain Lactobacillus plantarum (LPLDL), as BioStatin, and cholesterol reduction supplement CholBiome x3 as BioStatin Platinum.

OptiBiotix business development director Luis Gosálbez said the requirement for annual and increasing guaranteed minimum sales orders “helps builds recurring revenues and extends the sale of LPLDL into another territory to support further sales growth”.

Shares in OptiBiotix were up 2% to 84p in early trading on Monday.


Mon, 10 Jun 2019 08:15:00 +0100
<![CDATA[RNS press release - License agreement for CholBiome® in Vietnam ]]> Mon, 10 Jun 2019 07:00:03 +0100 <![CDATA[Media files - Proactive meets new director of OptiBiotix Health's prebiotics division ]]> Tue, 04 Jun 2019 11:35:00 +0100 <![CDATA[RNS press release - Director's Dealing ]]> Wed, 29 May 2019 15:17:21 +0100 <![CDATA[Media files - OptiBiotix appoints US-based chief executive for ProBiotix Health ]]> Tue, 28 May 2019 16:04:00 +0100 <![CDATA[News - OptiBiotix names probiotics veteran as CEO of ProBiotix Health ]]> OptiBiotix Health PLC (LON:OPTI) has appointed Stephen Prescott as chief executive officer (CEO) of its wholly-owned subsidiary, ProBiotix Health.

Prescott, who will be based in the USA, was previously vice president of Marketing and Applications at Probi AB, a Swedish probiotic company that had annualised sales of 604mln Swedish krona in 2018.

WATCH: OptiBiotix appoints US-based chief executive for ProBiotix Health

Prior to joining Probi, he spent four years as a global probiotic product manager at Dupont, the US conglomerate that merged with Dow Chemical in 2015.

ProBiotix is OptiBiotix’s division that is focused on the development of probiotics - healthy bacteria - to reduce cardiovascular risk.

"Stephen's experience and track record of growing probiotic sales in international markets bring specialist commercial and industry expertise to OptiBiotix's wholly- owned probiotic subsidiary, ProBiotix Health Ltd,” said Stephen O'Hara, the chief executive officer of OptiBiotix.

“His network of contacts provides access to international markets which we hope will continue to drive revenue growth of LPLDL in supplement, food, and pharmaceutical products around the world,” he added.

Tue, 28 May 2019 07:31:00 +0100
<![CDATA[RNS press release - Appointment of CEO of ProBiotix Health ]]> Tue, 28 May 2019 07:00:09 +0100 <![CDATA[News - OptiBiotix Health - the commercial momentum continues to build ]]> The commercial momentum at OptiBiotix Health PLC (LON:OPTI) continues to build.

After a string of deals for its health products, including one earlier this week, the company said it had inked an exclusive agreement in Poland.

The tie-up gives local operator Extensor the rights to distribute OptiBiotix’s GoFigure weight management line across the country.

Sales and marketing director, Christina Wood, said: “This is the first step in taking OptiBiotix's own label GoFigure products to international markets.

“This increases brand recognition and value in addition to creating a demand for SlimBiome, the functional ingredient within GoFigure products.

“This means we are able to derive revenue from both the sale of our own brand GoFigure products and SlimBiome."

Focused on the human microbiome, OptiBiotics has developed a series of products and potential treatments focused on changing the gut flora to tackle obesity, high cholesterol and diabetes.

Wed, 22 May 2019 07:49:00 +0100
<![CDATA[RNS press release - GoFigure® distribution agreement for Poland ]]> Wed, 22 May 2019 07:00:02 +0100 <![CDATA[News - OptiBiotix to target blood pressure market through licensing deal with Nutrilinea ]]> Life sciences business OptiBiotix Health PLC (LON:OPTI) has signed a licence agreement with Nutrilinea, an Italian manufacturer of food supplement formulations.

Under the terms of the agreement, Nutrilenea has been given the rights to use OptiBiotix’s cholesterol and blood pressure-reducing LPLDL product in a food supplement for the reduction of high blood pressure (hypertension).

READ OptiBiotix Health enters precision nutrition field with Spanish LPLDL licensing deal

Nutrilinea will cover the cost of all product development, manufacturing and human studies in return for 12 months exclusivity for the European market, excluding the UK - ProBiotix has exclusivity for the UK and all other markets outside Europe.

Nutrilinea currently produces the OptiBiotix’s CholBiome, CholBiomex3 and SlimBiome Medical products and has technology that enables the production of multilayer tablets used in CholBiomex3 that will also be used for this new product.

"We are delighted to announce this deal with Nutrilinea who are covering the cost of product development, manufacturing and human studies, for a food supplement to reduce blood pressure,” said Dr Luis Gosalbez, the business development director at OptiBiotix.

“This broadens the use of LPLDL beyond cholesterol reduction and creates new market opportunities in the field of cardiovascular health. Hypertension is a global health issue which is on the rise where there are very few active ingredients or supplements proven to lower blood pressure in humans. The development of a hypertension product containing LPLDL has the potential to address a large global market of unmet clinical need," he added.

Mon, 20 May 2019 07:47:00 +0100
<![CDATA[RNS press release - License agreement for LPLDL® ]]> Mon, 20 May 2019 07:00:05 +0100 <![CDATA[RNS press release - Notice of AGM ]]> Fri, 17 May 2019 07:00:04 +0100 <![CDATA[News - OptiBiotix inks Thai deal for weight-loss product ]]> OptiBiotix Health PLC (LON:OPTI) has signed an exclusive distribution deal for its weight loss product in Thailand.

The three-year agreement with Primo Trading will see the Thai company buy a minimum of 500kg of SlimBiome in the first 12 months, rising to 5,000kg by year-three. It has already made an initial 100kg purchase.

The product appears to be gaining commercial traction in Asia with approval in India opening the way for sales into one of the region’s largest markets.

“The growing obesity crisis has opened up an opportunity in these markets for SlimBiome where food supplements and functional holistic products are readily accepted,” said Christina Wood, sales and marketing director at OptiBiotix.”

Thailand, for example, is experiencing an obesity wave with one in three men and 40% of women now classified as overweight. The country is now the second heaviest in Asia after Malaysia, mainly as a result of increasing fast food outlets and high sugar usage throughout the food industry.

Wood went on: “The value gained from our industry awards, clinical studies and recent medical device approval has given our products clear differentiation over other weight loss products.

“The team at Primo have already identified key areas for SlimBiome and are in the process of formulating SlimBiome containing products to meet local tastes.”

OptiBiotix’s discoveries focus on gut health and the growing realisation that changes to the human microbiome are able improve health. As well as weight-loss products it is developing compounds to treat diabetes and high cholesterol.

Tue, 14 May 2019 07:23:00 +0100
<![CDATA[RNS press release - Distribution Agreement for SlimBiome® in Thailand ]]> Tue, 14 May 2019 07:00:04 +0100 <![CDATA[News - OptiBiotix Health enters precision nutrition field with Spanish LPLDL licensing deal ]]> A Spanish foods giant has signed a licensing agreement to use OptiBiotix Health PLC’s (LON:OPTI) cholesterol and blood pressure-reducing LPLDL strain in some of its products.

The agreement gives Instituto Español de Nutrición Personalizada (IENP) non-exclusive rights to manufacture and market food supplements containing LPLDL in Spain for the next three years.

IENP is the precision nutrition branch of CAPSA Food, one of Spain’s largest food conglomerates which turns over more than €700mln a year.

READ: Opti sets launch date for weight management product

It has developed a test that analyses gut microbiome – the bacteria living in the intestine – which it then uses to place customers on different, targeted food supplement regimes to help get their microbiome back to healthy.

Under the terms of the deal, IENP will use its network to market the product in supermarkets, department stores, pharmacies, and online across Spain.

“We are delighted to enter the field of personalised and precision nutrition, one of the fastest-growing and highest-value sectors within the food industry,” said OptiBiotix’s business development director, Luis Gosálbez.

“Within two years of launch, we now have products being sold by numerous partners in over 30 countries around the world.

“We see this agreement as another step to growing revenues, market presence, and brand value of LPLDL, the 'Intel' inside a wide range of products in consumer and pharmaceutical markets around the world.”

Tue, 07 May 2019 07:20:00 +0100
<![CDATA[RNS press release - License agreement for LPLDL® ]]> Tue, 07 May 2019 07:00:06 +0100 <![CDATA[RNS press release - Investor evening ]]> Thu, 02 May 2019 07:00:05 +0100 <![CDATA[News - OptiBiotix sets launch date for weight management product ]]> OptiBiotix Health PLC (LON:OPTI) said it is launching its weight management product SlimBiome Medical on May 7.

Its commercial debut will be made at a conference called Vitafoods Europe 2019, being held in Geneva.

SlimBiome is CE marked and helps reduce hunger pangs. It can be used as part of a calorie-restricted diet to achieve sustainable weight loss.

“The launch allows us to continue to deliver on our sales strategy of building multiple revenue streams across various sales channels because it will help us accelerate the expansion our distribution and sales network in Europe and beyond and support recent distribution agreements we have established,” said Fred Narbel, managing director of OptiBiotix’s Prebiotics division.

Wed, 01 May 2019 07:56:00 +0100
<![CDATA[RNS press release - SlimBiome launch to EU market at Vitafoods Europe ]]> Wed, 01 May 2019 07:00:14 +0100 <![CDATA[Media files - OptiBiotix set for a strong 2019 as agreements convert into revenues ]]> Tue, 30 Apr 2019 15:58:00 +0100 <![CDATA[News - OptiBiotix Health building a commercial head of steam ]]> OptiBiotix Health PLC (LON:OPTI) said expects commercial traction and revenues to grow after signing a raft of deals for its health products.

Having developed new strains of bacteria that target gut microbiome to tackle conditions such as high cholesterol, diabetes and obesity, it has seen significant commercial demand for its technology.

“We look forward to converting this interest into agreements in new territories and application areas in the months ahead to continue rapidly growing revenues in this new and exciting area of science which has the potential to revolutionise the future of healthcare,” said the company in a statement summarising the 12 months ended November 30 last year.

Among the highlights was a five-year deal with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply supplements and drug products containing OptiBiotix’s LPLDL bacteria strain in India.

It also gas an exclusive agreement with a US company for the LPLDL that carries six-figure milestone payments.

Coveted award

Weight loss ingredient SlimBiome, meanwhile, won a coveted award at the Food Matters event.

Commercial and critical success has been backed up by a growing body of work that essentially burnishes the scientific credential of its microbiome-targeting technology.

“As existing deals contribute to full-year revenues, partners continue to grow sales with new product launches, and as new agreements continue to be signed we anticipate further revenue growth in 2019,” said chief executive, Stephen O’Hara.

In the last financial, turnover grew 543% half-on-half and 169% year-on-year to £191,000. As is common for a company at this formative stage of its commercial development, OptiBiotix was loss-making. The operating loss was just under £1.5mln, £627,906 less than the year earlier as administrative expenses fell 17.5%.

At the period-end the firm had £1.33mln, rising to £1.67mln following the reclamation of R&D tax credits. In December it raised £1.025mln via a convertible loan in preparation for the potential float of the company’s ProBiotic Health arm. OptiBiotix confirmed it is still mulling the potential demerger.

Mon, 29 Apr 2019 07:48:00 +0100
<![CDATA[RNS press release - Final Results ]]> Mon, 29 Apr 2019 07:00:11 +0100 <![CDATA[News - OptiBiotix buoyed by UK launch of SlimBiome Medical ]]> OptiBiotix Health PLC (LON:OPTI) shares were buoyed on Wednesday after it launched its SlimBiome Medical weight management product in the UK market.

The company, which develops compounds to help tackle obesity, high cholesterol and diabetes, said SlimBiome would be available to buy from its website in boxes of 30 single-dose sachets from 29 April.

READ: OptiBiotix Health gets licence to manufacture weight management product SlimBiome in India

Opti also reported prelaunch sales to Bridge4 Health Ltd, a health and well-being centre based in Leicester, which would conduct a three-month field trial of the product to support weight loss among its gym members.

Fred Narbel, managing director of Opti’s Prebiotics division, said the UK launch would allow the group to “build early revenues at high margin through direct consumer sales”.

The launch follows SlimBiome receiving a CE mark in November last year, which allows it to be freely marketed within the European Economic Area (EEA).

READ: OptiBiotix surges as SlimBiome granted CE mark and medical device status

Since receiving the mark, the company has signed a slew of distribution deals for countries including Italy, Spain, Greece, Cyprus and Bulgaria.

More recently, the group has expanded its international presence, receiving a licence from the Food Standards and Safety Authority India earlier in April to manufacture SlimBiome in the country.

In mid-morning trading, OptiBiotix shares were up 1.7% at 82.9p.

 -- Adds share price --

Wed, 24 Apr 2019 07:34:00 +0100
<![CDATA[RNS press release - SlimBiome® Medical launches in UK market ]]> Wed, 24 Apr 2019 07:00:02 +0100 <![CDATA[News - OptiBiotix Health gets licence to manufacture weight management product Slimbiome in India ]]> OptiBiotix Health PLC (LON:OPTI) said it has received a licence from the Food Standards and Safety Authority India (FSSAI) for its award-winning weight management product, SlimBiome to be manufactured in India.

The AIM-listed life sciences firm said approval was gained by OptiBiotix's manufacturing partner, Zeon Life Sciences, for both SlimBiome and SlimBiome containing products.

READ: OptiBiotix jumps as it inks supply and profit sharing agreement for SlimBiome in India

It pointed out that FSSAI licence approval involves both ingredient and quality verification to ensure the product and manufacturing process is of a high standard and is an essential regulatory requirement to manufacture and distribute food products in India.

The licence approval allows Zeon to fulfil orders arising from OptiBiotix's recent visit to India for SlimBiome and SlimBiome containing products in its own manufacturing site. 

The group said: ”This is a strategic step by OptiBiotix to add manufacturing in Asia to the supply chain and extend the market opportunity for its patented award-winning weight management product into the fast-growing Indian market with an established partner.”

It noted that Zeon includes major Indian and international healthcare companies such as Danone, GNC, Decathlon, Sun Pharma and Herbalife amongst its customers and was awarded Nutraceutical Manufacturing Company of the Year in 2017 by The Associated Chambers of Commerce and Industry of India.

Stephen O'Hara, OptiBiotix’s CEO commented: "Achieving FSSAI approval so quickly is a significant achievement and is an important step in completing the supply chain to meet the needs of existing and new corporate partners in India and Southern Asia.

“This agreement is another step in a strategy designed to build multiple revenue streams from ingredient sales, and white label and own label branded consumer and pharmaceutical products across multiple channels with industry partners from around the world."

OptiBiotix revealed at the start of January this year that it had inked an agreement with Zeon, granting the firm an exclusive licence to manufacture and supply SlimBiome in India in return for a 50% share of the profits.

Thu, 11 Apr 2019 07:52:00 +0100
<![CDATA[RNS press release - SlimBiome® receives approval from FSSAI in India ]]> Thu, 11 Apr 2019 07:00:03 +0100 <![CDATA[Media files - OptiBiotix Health signs three-year agreement for SlimBiome in Bulgaria ]]> Wed, 10 Apr 2019 10:53:00 +0100 <![CDATA[News - OptiBiotix inks distribution deal for SlimBiome in Bulgaria ]]> OptiBiotix Health PLC (LON:OPTI) has signed a three-year agreement for the distribution of its SlimBiome weight loss product in Bulgaria.

The partner company, which was not named due to commercial interests and to protect launch plans, had “an established track record” of taking new products to pharmacies and wholesalers via its distribution network in the Balkan country.

WATCH: OptiBiotix Health signs three-year agreement for SlimBiome in Bulgaria

The agreement would grant the firm exclusive distribution rights in Bulgaria in return for meeting annual sales targets, OptiBiotix said.

Fred Narbel, managing director of OPTI’s prebiotics division, added that the partner company expected to place an early order for a consumer launch of the product “in the near future”.

“We are delighted at the high level of interest we have received in SlimBiome from an industry which recognises the value of protective patents and trademarks, two industry awards, clinical studies demonstrating safety and efficacy, and now a medical device registration and CE mark. These all provide a clear differentiation from other weight loss products. increasing the likelihood of commercial success.”

The Bulgarian deal is the second partnership agreed for SlimBiome in the last three weeks, with OPTI having signed a distribution agreement for the product in Italy and Spain back on 20 March.

In early trading on Tuesday, OptiBiotix shares were down 1.2% at 82p.

--Adds share price--

Tue, 09 Apr 2019 07:32:00 +0100
<![CDATA[RNS press release - SlimBiome® Medical agreement for Bulgaria ]]> Tue, 09 Apr 2019 07:00:03 +0100 <![CDATA[RNS press release - Grant of Options ]]> Wed, 27 Mar 2019 15:18:03 +0000 <![CDATA[News - OptiBiotix Health sweetener gaining traction with potential customers ]]> OptiBiotix Health PLC (LON:OPTI) shares rose on Wednesday as it appears to be making significant commercial headway with its next-generation sweetener.

Investors were told it has reached an outline deal with an unnamed US firm, which has funded pilot production of two batches of the SweetBiotix sweet fibre product.

READ: OptiBiotix Health chief outlines critical new SlimBiome distribution deal

“Once a binding commercial agreement has been reached, this will be announced to the market,” the company said.

At the same time, it disclosed it is in late-stage discussions with a global partner to jointly develop a lower sugar, lower calorie product.

The deals mooted are in addition to those already brokered by OptiBiotix.

Wider reach

In the same announcement, the firm said the latest data it published on its next-generation sweetener “stimulated interest from a wider range of partners”.

To recap, gut model studies showed OptiBiotix’s sweeteners enhanced the gut microbiome, significantly increasing the number and activity of bacterial species typically associated with good gut health.

In doing so, they outperformed traditional flavour enhancers such as stevia and mogrosides. The results were presented at the ProBiota conference last month.

“[They] are, to the best of our knowledge, the first reports of high intensity derived sweeteners impacting on the gut microbiome,” the company said.

“This functionality, published at a major scientific conference, has stimulated interest from a wider range of partners looking for functionality and health benefits in their products.”

In afternoon trading, shares in Optibiotix were 3.7% higher at 81.10p.

 -- Adds share price --

Wed, 27 Mar 2019 08:08:00 +0000
<![CDATA[RNS press release - SweetBiotix®: Scientific and commercial update ]]> Wed, 27 Mar 2019 07:43:02 +0000 <![CDATA[RNS press release - SweetBiotix®: Scientific and commercial update ]]> Wed, 27 Mar 2019 07:00:02 +0000 <![CDATA[RNS press release - Price Monitoring Extension ]]> Mon, 25 Mar 2019 11:00:19 +0000 <![CDATA[Media files - OptiBiotix Health chief outlines critical new SlimBiome distribution deal ]]> Thu, 21 Mar 2019 16:01:00 +0000 <![CDATA[News - OptiBiotix signs exclusive SlimBiome distribution agreement in Italy and Spain ]]> OptiBiotix Health PLC (LON:OPTI) has signed an exclusive agreement with DKSH International to distribute its SlimBiome weight management ingredient in Italy and Spain.

In order to maintain its market exclusivity, the multi-billion-dollar Swiss firm will have to meet certain sales targets, which Opti believes will maximise the financial return for both parties.

It should also provide some surety of income over the next three years, the AIM-quoted company added.

WATCH: Extension to supply agreement 'reflects growing confidence' in OptiBiotix's LPLDL strain

“We are delighted that DKSH will be bringing their marketing and sales expertise to promote the sale of SlimBiome,” said sales and marketing director Christina Wood.

“DKSH is a highly successful global corporation with a strong positioning in both consumer goods, including foods and beverages, as well as healthcare and technology; key areas for our weight management products.”

SlimBiome is an appetite-suppressing ingredient which can be added to things such as snack bars, shakes and even coffee.

Research has shown that it can reduce hunger and cravings for sweet, fatty and savoury foods, helping people to lose as much as 3lbs a week.

Wood added: “We hope combining these attributes with DKSH's sales, marketing and distribution expertise will generate substantial revenues in the months and years ahead.”

Wed, 20 Mar 2019 07:31:00 +0000
<![CDATA[RNS press release - Exclusive distribution agreement for SlimBiome® ]]> Wed, 20 Mar 2019 07:00:04 +0000 <![CDATA[Media files - Extension to supply agreement 'reflects growing confidence' in OptiBiotix's LPLDL strain ]]> Mon, 18 Mar 2019 13:11:00 +0000 <![CDATA[News - OptiBiotix extends LPLDL supply agreement with German probiotics firm HLH ]]> OptiBiotix Health plc’s (LON:OPTI) subsidiary, ProBiotix Health, has extended its original supply agreement with German probiotics supplier HLH Biopharma.

The new three-year agreement grants HLH an exclusive licence to produce, package and commercialise a capsule containing Opti’s cholesterol-reducing LPLDL strain in Germany.

In order to maintain exclusivity in Germany, HLH will have to double its order volumes every year.

READ: OptiBiotix Health’s cholesterol product recognised as safe by expert US panel

As part of the tie-up, HLH has also been granted a non-exclusive licence to produce, package and commercialise products containing LPLDL in Austria, Switzerland and the United Arab Emirates.

“We are pleased to announce this extension of terms and territory with HLH who is one of Europe's leading suppliers of probiotics to the pharmacy market,” said chief executive Stephen O’Hara.

“The agreement recognises the success of HLH in building sales of its LPLDL containing Lactobact brand in Germany and extends the terms and territory to support further sale growth.

“This is another step in extending the geographical reach of LPLDL as it builds recurring revenue streams and increases brand recognition and the value of its products.

“This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world.”

Fri, 15 Mar 2019 07:17:00 +0000
<![CDATA[RNS press release - Extension of term and territories for LPLDL® ]]> Fri, 15 Mar 2019 07:00:03 +0000 <![CDATA[RNS press release - Exercise of Warrants ]]> Wed, 13 Mar 2019 15:42:25 +0000 <![CDATA[Media files - OptiBiotix cholesterol product 'generally recognised as safe' by US independent expert panel ]]> Thu, 21 Feb 2019 12:02:00 +0000 <![CDATA[News - OptiBiotix Health cholesterol product generally recognised as safe (GRAS) by US independent expert panel ]]> OptiBiotix Health plc (LON:OPTI) said its cholesterol product had been generally recognised as safe (GRAS) by an independent expert panel in the US.

The company, which is developing products to tackle obesity, cardiovascular disease and diabetes, said sign-off for its Lactobacillus plantarum LPLDL probiotic strain represented a significant milestone.

WATCH: OptiBiotix cholesterol product 'generally recognised as safe' by US independent expert panel

That’s because GRAS designation is required for food additives in the States. In the case of probiotics, it is strain-specific.

Assessment involves submitting an extensive technical dossier for evaluation.

The GRAS panel that reviewed LPLDL concluded the bacteria strain was safe for use in food and beverages at a concentration of up to 10bn colony forming units per serving. 

This is more than double the dose found to significantly reduce cholesterol and blood pressure in a human trial conducted by Reading University.

OptiBiotix chief executive Stephen O’Hara said: “This is a significant achievement and a major commercial milestone as it expands the potential applications of LPLDL from use as a supplement to use as a functional ingredient in a wide range of food, dairy, beverage, and high-value medical food applications, across the USA.

“In addition, obtaining GRAS status is increasingly being seen by large US corporates as a key requirement to independently validate the safety of commercial probiotic strains in supplements and as such, is a major point of differentiation from other probiotics, as very few strains currently have this status.”

Thu, 21 Feb 2019 07:30:00 +0000
<![CDATA[RNS press release - LPLDL® determined GRAS by an Expert Panel in US ]]> Thu, 21 Feb 2019 07:00:02 +0000 <![CDATA[News - OptiBiotix Health hails commercial and scientific interest in its products following industry conference ]]> OptiBiotix Health plc (LON:OPTI) said it was pleased with the scientific and commercial interest around presentations made to an industry conference held in Copenhagen last week.

The company, which is developing compounds to tackle obesity, high cholesterol and diabetes, provided three separate updates at ProBiota, an event for the prebiotic, probiotic and the microbiome-focused food and pharma industries.

READ: OptiBiotix Health reveals commercial traction for its innovative new products

A study of the SweetBiotix revealed the sweetener product to be less bitter with fewer “off-flavours” than Stevia, the current best in class.

More importantly, researchers found it to have a microbiome modulating effect.

The microbiome in the gut helps digest food, produces certain vitamins, regulates the immune system, and protects against disease-causing bacteria.

“Whilst previous studies have demonstrated that these fibres have high sweetness and no aftertaste, this is the first study to demonstrate a positive effect on the microbiome,” OptiBiotix explained.

“This creates a clear differentiator to other sweeteners on the market and an opportunity to replace unhealthy sugars with healthy fibres in a range of food and beverage products and as an ingredient in its own right.”

OptiBiotix also presented data on the antimicrobial activity of its Lactobacillius Plantarum LPLDL bacteria, which is being developed to reduce cholesterol.

Research carried out by the University of Reading showed it also worked against a wide range of pathogens, including Salmonella, E.coli O157, and, significantly, Clostridium difficile.

This may have the potential to widen LPLDL's commercial opportunities to include gut health and the prevention of traveller's diarrhoea, OptiBiotix said.

Attendees at the Copenhagen conference were also furnished with results from a weight loss trial carried out by Roehampton University using Slimbiome.

This revealed the product had an impact on satiety (feeling full), weight loss and gut microbiome composition in overweight and obese women.

OptiBiotix chief executive Stephen O'Hara said: “These studies, and the publications and presentations at internationally renowned events, are part of a strategy of developing microbiome products with a strong scientific and clinical evidence base with key opinion leader support.

“This provides clear product differentiation which can be translated into evidence-based product consumer claims.”

Wed, 20 Feb 2019 08:18:00 +0000
<![CDATA[RNS press release - Presentations at ProBiota - 2019 ]]> Wed, 20 Feb 2019 07:00:05 +0000